DAX lifted by pharma stocks

The German equity market has been given a boost by talk of takeovers in the pharmaceutical sector.

The DAX is trading at 9550, up 0.8% on the day, as a flurry of merger and acquisition news from the pharmaceutical industry has driven the overall market higher.

There is speculation that Pfizer is launching a £60 billion takeover of AstraZeneca, while GlaxoSmithKline is selling its oncology unit to Novartis, and will buy its animal health care division.

Even though none of the companies mentioned above are listed on the German exchange, the corporate activity has pushed pharmaceutical stocks of Merck KGaA and Bayer AG higher, 2.5% and 3.2% respectively.

In recent months, the DAX has found it difficult to hold ground above the 9600 level, and the unrest in Ukraine has put pressure on Germany equities. As I previously stated, the west and Moscow are trying to find a political solution but if hostilities escalate in Ukraine, we could retreat to the 100-day moving average of 9462.

Germany 30 chart

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen. 79% van de retailbeleggers lijdt verlies op de handel in CFD’s met deze aanbieder.
Het is belangrijk dat u goed begrijpt hoe CFD's werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen.